<DOC>
	<DOCNO>NCT00752869</DOCNO>
	<brief_summary>This study use two FDA approve medication : Testosterone study medication , Dutasteride ( Avodart 0.5mg/day ) . Half subject receive dutasteride half receive placebo . The study medication take 12 month . The subject participate study men already take testosterone supplement low testosterone level may cause experience sexual function difficulty , fatigue symptom . Testosterone adverse effect cause enlarge prostate ( Benign Prostatic Hypertrophy ) ( BPH ) . Dutasteride ( Avodart ) approve medication use decrease prostate size , prevent urinary symptom reduce risk surgery . The researcher would like see take dutasteride testosterone time prevent adverse effect testosterone time get positive benefit testosterone . There 6 schedule visit study 2 diagnostic test call TRUS ( TransRectal UltraSound ) , evaluate prostate size . The six visit include consent , blood work , two sexual function questionnaire , physical examination , physical measurement , study medication teach dispense study medication .</brief_summary>
	<brief_title>Efficacy Study Use Dutasteride ( Avodart ) With Testosterone Replacement</brief_title>
	<detailed_description>Termination criterion 1 . Serum AST ALT &gt; 3 time ULN 2 . Total serum bilirubin &gt; 1.5 time ULN - study termination patient document Gilberts disease isolate bilirubin elevation unless exceeds 2.5x upper limit normal . 3 . Hematocrit &gt; 55 % 4 . Subject experience unacceptable intolerable adverse effect . 5 . Subject non-compliant study protocol . 6 . Subject need take medication would interfere study measurement 7 . Subject develop prostate breast cancer</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>1 . Subjects currently stable testosterone replacement therapy 3 month ' duration use either approve transdermal product Androgel® Testim® , injection testosterone enanthate cypionate morning serum testosterone concentration within normal range ( 300 1000 ng/dl ) . These dispense either prescription injection PI coPI office . 2 . Total Serum PSA &gt; 1.5 10 ng/mL If total serum PSA &gt; 4ng/mL , investigator , qualified urologist , perform 12core prostate biopsy prior entry unless biopsy already perform within past 6 month . If PSA rise 4 time study , patient refer urology biopsy . Patients suspicious rise PSA &gt; 1.0 ng/ml/yr repeat PSA perform within one month original value . If rise PSA remain &gt; 1.0 ng/ml/yr , patient undergo prostate biopsy . b . If individual negative biopsy 6 month previously , documentation stable PSA since time , ie , sustain increase &gt; 1.0ng/ml . 3 . Subject able read comprehend inform consent document . 4 . If subject current replacement therapy hypopituitarism multiple endocrine abnormality , subject must stable dos thyroid hormone and/or adrenal replacement hormone least 14 day prior enrollment . 1 . Use medication include interactive dutasteride prior study 2 . Hematocrit great 51 % 3 . Prostate cancer men find prostate nodule initial exam subsequent positive biopsy 4 . No prostate surgery within 2 month entry 5 . No prior use finasteride , dutasteride within 6 month prior 6 . A history hepatic impairment abnormal liver function test ( defined ALT , AST , alkaline phosphatase bilirubin &gt; 1.5 time upper limit normal ) exception bilirubin elevation 2.0 time upper limit normal presence normal liver enzymes permit patient document Gilbert 's Disease . Subjects Gilbert 's disease exclude . 7 . No serum creatinine great 2.0 time upper limit normal 8 . No history alcohol abuse last 12 month 9 . Has receive medication clinical trial within 2 month enrollment 10 . Use antiandrogens , estrogens coumadin 11 . A history evidence newly discover prostate cancer ( e.g . positive biopsy ultrasound , suspicious DRE ) . In patient suspicious ultrasound DRE , include patient focal nodule , biopsy shall perform qualified urologist upon study entry unless one performed find negative within precede 6 month . 12 . History current prostate breast cancer 13 . Baseline EKG clinically significant abnormal rhythm abnormal QT interval 14 . Systolic blood pressure 170mmHg diastolic blood pressure 90 mm Hg baseline physical exam 15 . Clinically significant peripheral edema baseline physical exam 16 . History sleep apnea 17 . History psychiatric disorder major depression 18 . Consumption grapefruit juice within 7 day enrollment unwilling eliminate use grapefruit juice study period 19 . History allergy study medication 20 . Hemoglobin A1c &gt; 9 % noninsulin dependent diabetic 21 . Subjects abnormal thyroid function 22 . Subjects significantly elevate triglyceride</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>low testosterone</keyword>
</DOC>